about RPO group

Radiomolecular Precision Oncology

There is a forever difference in pace between fast preclinical discoveries and their slow translation into clinical practice due to a regulatory environment that curtails any effective translation. In order to narrow this gap RPO Group streamlines building a body of evidence around (the intellectual property claim of) an early compound, delivers value from limited datasets, expedites drug development routes, and avoids tunnel vision clearly differentiating between must have, nice to have, and abandon compounds.

backgorund

The rise of Radiotheranostics in Clinical Management

The current radiotheranostic revolution - primed for a rapid expansion in the coming years - is profoundly changing the multidisciplinary care of (metastatic) cancer patients, and may soon be among the most important pillars in clinical management. For Good.

At RPO Group, we enhance the development of radiotheranostics, focusing on surpassing traditional treatments in efficacy and safety. With a high failure rate of over 95% in clinical trials due to safety and efficacy issues, our use of advanced imaging technologies like SPECT-CT, PET-CT, and PET-MRI is key. We precisely identify suitable cancer patients for targeted therapies, leveraging radiotheranostics’ unique ability to switch between diagnostic and therapeutic modes within the same molecular structure. This strategy aims to increase the effectiveness of clinical trials and lead the way to safer, more focused cancer treatments.

Download our explainer infographic Download our flyer

Who's who?

Prof Dr Richard P Baum (MD PhD), Chairman, is the current Chairman of the Advanced Theranostic Centre for Radiomolecular Precision Oncology at CURANOSTICUM (Wiesbaden-Frankfurt, Germany), President of the Academy (International Centers for Precision Oncology (ICPO)), and Professor of Nuclear Medicine (University of Frankfurt-Main, Germany). Within RPO Scientific, he is the clinical and medical opinion leader, offering advice and consultancy on study strategy and design.

Prof Dr Andreas Türler (PhD), Head of Radiochemistry and Manufacturing, currently holds the chair of radiochemistry at University of Bern. Prof. Türler and his team established a GMP-certified radiopharmacy at the Insel University Hospital in Bern. Within RPO Group he is an internationally renowned expert in the field of chemistry and physics of radionuclide production for nuclear medicine.

Dr Hugo M L Jansen (PharmD MD PhD), CEO, is a clinical pharmacologist and nuclear radiologist. Within RPO Clinical, he now will act as business, imaging, medical and science liaison. With nearly 30 years of life science and clinical experience, Dr Jansen has an extensive background working with hospitals and companies focused on theranostics.

Delphine Remmy (PharmD), Head of Clinical Operations, has over 20 years experience in the pharmaceutical industry, from big pharma to start-up companies. Her main experience is Oncology, Hematology and Rare Diseases from Phase I to Phase III with a focus on early stage development. Within RPO Delphine will oversee the set-up and execution of all clinical studies, and serve as a liaison for our clients.

Iona Nicolson Bowles, Senior Study Director, has over 20 years experience across pharmaceutical, CRO and private cancer clinics with a strong focus in oncology. Knowledgable in all phases of trials from start up to close out with a particular interest in early development.

Extensive people management experience with a passion for coaching and mentoring, building high performance teams and leading change management in organisations.

Michael Payne-McGlen, Head of Imaging Operations, has 8 years of experience in Nuclear Medicine imaging across both clinical practice and clinical research. His expertise covers all aspects of image management and analysis of theranostics from Phase I through Phase III. He will lead end-to-end delivery of imaging services for RPO.